SKF 83822 hydrobromide

Pricing Availability   Qty
Description: Selective D1-like agonist
Chemical Name: 6-Chloro-2,3,4,5-tetrahydro-1-(3-methylphenyl)-3-(2-propenyl)-1H-3-benzazepine-7,8-diol hydrobromide
Purity: ≥98% (HPLC)
Citations (3)
Literature (4)

Biological Activity for SKF 83822 hydrobromide

SKF 83822 hydrobromide is a high affinity, selective dopamine D1-like receptor agonist. Ki values are 3.2, 3.1, 186, 66, 335, 1167, 1251 and 1385 nM at recombinant D1, D5, D2, D3, D4, 5-HT2A, α1A and α1B receptors respectively. Stimulates adenylyl cyclase (EC50 = 65 nM) but not phosphoinositide hydrolysis. Induces extreme arousal and hyperlocomotion following subcutaneous administration in monkeys.

Technical Data for SKF 83822 hydrobromide

M. Wt 424.76
Formula C20H22ClNO2.HBr
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 74115-10-9
PubChem ID 12909789
Smiles ClC1=C(O)C(O)=CC2=C1CCN(CC=C)CC2C3=CC=CC(C)=C3.Br

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for SKF 83822 hydrobromide

Solvent Max Conc. mg/mL Max Conc. mM
ethanol 3.44 10
DMSO 34.38 100

Preparing Stock Solutions for SKF 83822 hydrobromide

The following data is based on the product molecular weight 424.76. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.35 mL 11.77 mL 23.54 mL
5 mM 0.47 mL 2.35 mL 4.71 mL
10 mM 0.24 mL 1.18 mL 2.35 mL
50 mM 0.05 mL 0.24 mL 0.47 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for SKF 83822 hydrobromide

Certificate of Analysis / Product Datasheet
Select another batch:

References for SKF 83822 hydrobromide

References are publications that support the biological activity of the product.

Undie et al (1994) Evidence for a distinct D1-like DA receptor that couples to activation of phosphoinositide metabolism in brain. J.Neurochem. 62 2045 PMID: 7908949

Peacock and Gerlach (2001) Aberrant behavioural effects of a DA D1 receptor antagonist and agonist in monkeys: evidence of uncharted DA D1 receptor actions. Biol.Psychiatry 50 501 PMID: 11600103

O'Sullivan et al (2004) SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled D1-like receptors: behavioural topography. Eur.J.Pharmacol. 486 273 PMID: 14985049

If you know of a relevant reference for SKF 83822 hydrobromide, please let us know.

View Related Products by Target

View Related Products by Product Action

View all D1 and D5 Receptor Agonists

Keywords: SKF 83822 hydrobromide, SKF 83822 hydrobromide supplier, Selective, D1-like, agonists, Dopamine, D1, Receptors, D5, dopaminergic, SKF83822, hydrobromide, and, 2075, Tocris Bioscience

3 Citations for SKF 83822 hydrobromide

Citations are publications that use Tocris products. Selected citations for SKF 83822 hydrobromide include:

Kramar et al (2014) DA in the dorsal hippocampus impairs the late consolidation of cocaine-associated memory. J Neurosci 39 1645 PMID: 24442095

Ruskin et al (2013) Ketogenic diet improves core symptoms of autism in BTBR mice. PLoS One 8 e65021 PMID: 23755170

Urizar et al (2011) CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Neuropsychopharmacology 7 624 PMID: 21785426

Do you know of a great paper that uses SKF 83822 hydrobromide from Tocris? Please let us know.

Reviews for SKF 83822 hydrobromide

There are currently no reviews for this product. Be the first to review SKF 83822 hydrobromide and earn rewards!

Have you used SKF 83822 hydrobromide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Dopamine Receptors Scientific Review

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.